Ethicon, Inc., a worldwide leader in surgical care, announced that the company has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the Fibrin Pad, a novel product candidate that combines Ethicon's biomaterials and plasma-derived biologics (Human Fibrinogen and Human Thrombin), to aid in stopping soft tissue bleeding during surgery. "Excessive bleeding during surgical procedures is a serious and challenging problem... 
More...
More...